6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 6-K

__________________

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

September 21, 2018

Commission File Number: 001-38283

__________________________________

InflaRx N.V.

__________________________________

Winzerlaer Str. 2

07745 Jena, Germany

(+49) 3641 508180

(Address of principal executive offices)

__________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On September 21, 2018, InflaRx N.V. (“InflaRx”) held an Extraordinary General Meeting of Shareholders. At the meeting, InflaRx shareholders approved the appointment of Mr. Jens H. Holstein as a non-executive director. Mr. Holstein’s term as a director is effective immediately and will end upon the Annual General Meeting of Shareholders to be held in 2021. InflaRx issued a press release announcing the result of its Extraordinary General Meeting of Shareholders and the appointment of Mr. Holstein as a non-executive director. Mr. Holstein will also replace Mr. Kübler on the Company's audit committee.

INCORPORATION BY REFERENCE

Exhibit 99.1 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jena, Germany, September 21, 2018.

INFLARX N.V.
By:	/s/ Niels Riedemann
	Name:  Niels Riedemann Title:    Chief Executive Officer

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	InflaRx N.V. Press Release dated September 21, 2018

EX-99.1

Exhibit 99.1

 

InflaRx N.V. Announces Appointment of Jens Holstein
to Board of Directors

Jena, Germany, September 21, 2018 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, announced today that Jens Holstein has been appointed as a new board member of InflaRx, serving as Non-Executive Director. The appointment was approved by the Extraordinary General Meeting of shareholders held today in Amsterdam, the Netherlands. Mr. Holstein has extensive management experience in the biotechnology and healthcare industry and currently serves as CFO of MorphoSys AG.

“We are delighted to have Mr. Jens Holstein join our Board of Directors,” said Niels Riedemann, Chief Executive Officer and founder of InflaRx. “Mr. Holstein brings with him in depth industry experience through numerous financial leadership positions he held in both biotech and healthcare over the course of his career. His expertise will be invaluable to InflaRx as we move forward.”

“I am pleased to have the opportunity to join the InflaRx Board of Directors at such an important juncture in the company´s development,” stated Mr. Holstein. I am impressed with what the team has accomplished thus far, and I very much look forward to contributing to InflaRx’s continued success in the years to come.”

Mr. Holstein currently serves as Chief Financial Officer of MorphoSys AG, a dual-listed (Frankfurt and Nasdaq) drug development company. He joined MorphoSys in 2011 from Fresenius, a global healthcare company, where he served as Regional CFO for the Europe/Middle East region of Fresenius Kabi AG, and as Managing Director of Fresenius Kabi Deutschland GmbH. Over his nearly 16 years at Fresenius, Mr. Holstein held a variety of financial and general management positions, including Regional CFO of Fresenius Kabi Asia Pacific Ltd., Managing Director of Fresenius ProServe GmbH and CFO

 

and Labor Director of the company's subsidiary, Wittgensteiner Kliniken AG. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry in Frankfurt and London. He holds a Diploma in Business Administration from the University of Muenster.

About InflaRx N.V.:

InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany as well as Ann Arbor, Michigan, and New York City, USA. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”. For further information please visit www.inflarx.com.

Contacts:

Investor Relations InflaRx N.V. Jordan Silverstein Head of Corporate Development and Strategy Jordan.silverstein[at]inflarx.de +49-3641-508180 Media Relations MC Services AG Katja Arnold, Andreas Jungfer Inflarx[at]mc-services.eu +49 89 210 228 0

 

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.